CG oncology, Inc. (CGON)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$74.67+0.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
CG Oncology is close to finishing a big Phase 3 trial. The trial targets bladder cancer and could lead to a new treatment. The company plans about $1.1 billion in revenue by end of 2026. Leadership changes may help the company run better.
The company keeps losing money and burning cash. Past earnings missed estimates many times. Key leaders have left, which may hurt progress. The drug approval is not guaranteed yet.
The stock trades about 15% below our fair value near $81. The market expects negative earnings growth over the next 3 to 5 years. Our view aligns with the Street on valuation but sees risks in execution.
Breaks if: Additional key executive departures in 2026
Breaks if: Operating loss worsens beyond negative $70M in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CGON represents a speculative growth investment, primarily focused on advancing its clinical trials and regulatory submissions. The current thesis state is cautious, given recent earnings misses and elevated risks in the near term.
The market appears to have a low fragility tier, indicating that it does not expect significant volatility in CGON's stock. However, the recent weak financial performance suggests that expectations may be tempered compared to its industry peers.
Fundamentals are likely to remain under pressure due to a high probability of an earnings miss in the near term. Management is focused on key milestones, but recent performance has been weak, which could impact investor sentiment.
The thesis hinges on the outcomes of the ongoing clinical trials and the ability to meet regulatory deadlines. Additionally, broader sector performance, particularly from leading companies, will influence CGON's momentum.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Control operating expenses and cash burn while advancing clinical programs.
Stated as a priority in 2 of last 2 quarters. Net loss increased from $60.2M in 2026-Q1 to $79.1M in 2026-Q2, driven by higher R&D and G&A expenses due to clinical and headcount growth. Management continues to manage operating losses amid advancing clinical programs, indicating ongoing cost discipline but increasing cash burn.
“Net loss $79.1 million; R&D $54.7 million; G&A $29.0 million.”
“Net loss $60.2 million; R&D $43.7 million; G&A $20.8 million.”
Breaks if: Topline data not reported by mid-2026
Complete and report topline data from the Phase 3 PIVOT-006 trial for intermediate-risk NMIBC in 2026.
Stated as a priority in 2 of last 2 quarters. Management reported that PIVOT-006 Phase 3 trial has accrued most target events and topline data is anticipated in first half 2026. The clinical milestone is on track with management's stated timeline, indicating delivering progress.
“PIVOT-006 has accrued the vast majority of target events; topline results expected soon.”
“PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy anticipated first half 2026.”
Breaks if: Revenue falls below $1 billion in FY26
In the 1 to 3 year view, CGON's prospects depend on successful clinical advancements and sector support, but risks remain elevated. Not investment advice.